alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › antiamyloid

antiamyloid

2 studies tagged antiamyloid, dated 2020-05-01 to 2023-03-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development 2023-03-01
  2. Passive antiamyloid immunotherapy for Alzheimer's disease 2020-05-01

Studies

2 studies carry this tag.

Date range

2020 to 2023

Top journals

  • Current opinion in psychiatry 1
  • Lancet regional health. Americas 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Lancet regional health. Americas 2023-03-01 Treatments

    In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating the drug's cognitive benefits.

  2. Passive antiamyloid immunotherapy for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Current opinion in psychiatry 2020-05-01 Treatments

    Antiamyloid therapy of Alzheimer's disease tackles the overproduction and clearance of the amyloid-beta peptide (Aβ).

All topic tags with their study counts